We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+0.54%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.46B
AUM Growth
-$483M
Cap. Flow
-$259M
Cap. Flow %
-10.54%
Top 10 Hldgs %
47.28%
Holding
112
New
8
Increased
8
Reduced
35
Closed
24

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$217M
2
IMRX icon
Immuneering
IMRX
+$60.5M
3
TNGX icon
Tango Therapeutics
TNGX
+$37.1M
4
CYTK icon
Cytokinetics
CYTK
+$29.4M
5
TYRA icon
Tyra Biosciences
TYRA
+$20.4M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$41.1M
2
TWST icon
Twist Bioscience
TWST
+$24.7M
3
XLRN
Acceleron Pharma
XLRN
+$22M
4
MASS icon
908 Devices
MASS
+$21.1M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
51
Inspire Medical Systems
INSP
$1.74B
$11.2M 0.46%
48,132
– –
ANAB icon
52
AnaptysBio
ANAB
$1.68B
$10.4M 0.42%
385,081
– –
ALGS icon
53
Aligos Therapeutics
ALGS
$34.9M
$10.3M 0.42%
26,687
-9,532
-26% -$3.77M
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.1M 0.41%
100,000
-68,150
-41% -$7.99M
DMTK
55
DELISTED
DermTech, Inc. Common Stock
DMTK
$9.63M 0.39%
300,000
-150,000
-33% -$5.27M
BEAM icon
56
Beam Therapeutics
BEAM
$2.84B
$8.7M 0.35%
100,000
– –
TVTX icon
57
Travere Therapeutics
TVTX
$5.78B
$8.49M 0.34%
+350,000
New +$6.43M
PLRX icon
58
Pliant Therapeutics
PLRX
$65M
$8.14M 0.33%
482,413
– –
ELDN icon
59
Eledon Pharmaceuticals
ELDN
$285M
$8.06M 0.33%
1,305,095
-110,405
-8% -$772K
ITOS
60
DELISTED
iTeos Therapeutics
ITOS
$7.79M 0.32%
288,330
– –
QURE icon
61
uniQure
QURE
$3.22B
$7.67M 0.31%
239,548
– –
VERU icon
62
Veru
VERU
$37.4M
$6.82M 0.28%
80,000
– –
MYOV
63
DELISTED
Myovant Sciences Ltd.
MYOV
$6.73M 0.27%
300,000
-242,499
-45% -$5.32M
APTO
64
DELISTED
Aptose Biosciences, Inc.
APTO
$6.54M 0.27%
6,667
-1,793
-21% -$2.24M
MORF
65
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.66M 0.23%
100,000
-89,774
-47% -$5.43M
VRDN icon
66
Viridian Therapeutics
VRDN
$2.67B
$5.63M 0.23%
342,562
-400
-0.1% -$5.87K
MRUS
67
DELISTED
Merus
MRUS
$5.5M 0.22%
250,000
-35,096
-12% -$753K
DCPH
68
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.91M 0.2%
144,439
– –
ATXS
69
DELISTED
Astria Therapeutics
ATXS
$4.89M 0.2%
552,903
-38,764
-7% -$371K
AKUS
70
DELISTED
Akouos Inc
AKUS
$4.58M 0.19%
394,500
– –
RCOR
71
DELISTED
Renovacor, Inc.
RCOR
$4.53M 0.18%
+500,000
New +$4.88M
MLTX icon
72
MoonLake Immunotherapeutics
MLTX
$1.55B
$4.28M 0.17%
430,000
– –
HARP
73
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$4.27M 0.17%
54,060
– –
DMRA
74
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$4.13M 0.17%
46,029
-24,125
-34% -$2.58M
TCRR
75
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$4.08M 0.17%
479,506
– –
1 2
3
4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Cormorant Asset Management held 112 positions worth $2.46B, down 16% from $2.94B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management withdrew a net $259M in Q3 2021, closing 24 positions and reducing 35 holdings. Its most notable exit was Twist Bioscience, an estimated $24.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Erasca worth $217M.

  • Cormorant Asset Management's largest Q3 2021 buy was Erasca: 10,505,550 shares worth $217M.
  • Cormorant Asset Management added most to Tango Therapeutics in Q3 2021, an estimated $37.1M increase.
  • Cormorant Asset Management's biggest Q3 2021 reduction was Atea Pharmaceuticals, cutting an estimated $41.1M.
  • Cormorant Asset Management fully exited Twist Bioscience in Q3 2021, selling an estimated $24.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.46B portfolio in Q3 2021.
  • Cormorant Asset Management opened 8 new positions and closed 24 in Q3 2021.
  • Cormorant Asset Management's portfolio value fell 16% quarter-over-quarter to $2.46B.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.